Plain-English translation of NCT04119024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called IL13Ra2 CAR T cells—immune cells that are taken from your own body, modified in a lab to better recognize and attack cancer, and then put back into you. The study is looking at whether this treatment is safe and whether it can help people with advanced melanoma or other solid tumors that haven't responded to other therapies.
Many people with advanced melanoma and other solid tumors run out of standard treatment options or their cancers stop responding to available drugs. This medication represents a different approach—using your own immune system as a personalized weapon against cancer—and researchers need to test whether it's safe and effective.
You likely qualify if…
You likely don't qualify if…
You will receive two chemotherapy drugs over several days to prepare your immune system, then have immune cells collected from your blood (leukapheresis). Those cells will be sent to a lab to be genetically modified, and then infused back into you through an IV. You'll have regular scans (CT or PET), blood tests, and biopsies to track how you're responding. If your disease progresses, you may be eligible for a second infusion. Follow-up visits continue for at least 15 years after treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States